Chemists pioneer metallodrug-antibiotic combination strategy to combat superbugs

Antimicrobial resistant (AMR) bacterial infections have become a serious problem threatening human health worldwide. The overuse of antibiotics has promoted drug-resistant mutations in bacteria, causing some bacteria to develop resistance to almost all clinically used antibiotics. 

In May 2024, the World Health Organization (WHO) updated its list of drug-resistant bacteria that pose the greatest threat to human health, among which Pseudomonas aeruginosa was listed as a high-priority pathogen.

READ MORE: Scientists uncover mechanisms that could weaken virulence of Pseudomonas aeruginosa

READ MORE: Scientists discover rules for breaking into Pseudomonas

Pseudomonas aeruginosa is a particularly dangerous bacterium that can cause a wide range of infections, including pneumonia, urinary tract infections, and bloodstream infections. It is known for its ability to develop resistance to antibiotics quickly, making it challenging to treat and posing a significant risk to immunocompromised patients, such as those in hospitals or with chronic illnesses. Given the urgency of the situation, it is essential to develop new treatment strategies to combat superbug infections.

Pepto-Bismol restores bactericidal function of antibiotics

Recently, a team led by Professor Hongzhe Sun from the Department of Chemistry at The University of Hong Kong, in collaboration with the University of Groningen (Netherlands) and Nankai University, has made a breakthrough in solving this challenging problem.

Their work has been published in the internationally renowned journal Nature Microbiology. The team’s work has shown the combination of different types of antibiotics with bismuth-based drugs (such as bismuth subsalicylate, commonly known as Pepto-Bismol) disrupts bacterial iron homeostasis, effectively restoring the bactericidal function of multiple antibiotics.

This combination therapy leads to the elimination of multi-drug resistant bacteria Pseudomonas aeruginosa. Their efficacy has been demonstrated in both bacterial-infected cells and in mouse models, providing crucial strategies for combatting the global threat of antibiotic resistance (AMR) and offering potential clinical applications.

In a recent feature article in Nature, Professor Hongzhe Sun stated, ‘The next epidemic is likely to be an infection caused by superbugs. We must be fully prepared for it and have powerful arsenals to treat such deadly infections.’

Metal compounds to target bacteria 

With increasing concern for antibiotic resistance, scientists and clinicians all over the world are tirelessly working to find new solutions. Antibiotic-resistant bacteria like Pseudomonas aeruginosa are a major global public health challenge. There is an urgent need to develop new antibiotics or enhance and prolong the antibacterial activity of existing clinical antibiotics.

Metal compounds have traditionally been used as antibacterial agents. Their multi-target mode of action allows them to interfere with multiple biological pathways in pathogens, resulting in a lower frequency of drug resistance.

In recent years, Professor Sun’s team has carried out extensive work to address the problem of ‘superbugs’. For example, metallodrugs such as bismuth citrate have effectively inhibited the activity of metallo-β-lactamase, an important enzyme that bacteria use to destroy commonly used antibiotics. His team also employed a dual ‘Trojan Horse’ strategy, using metallo-sideromycin to restore the activity of Cefiderocol, one of the latest antibiotics. Cefiderocol is ‘smuggled’ into bacterial cells through the bacteria’s uptake of ferric iron (Fe3+), enhancing its bactericidal effect. Additionally, a bismuth drug mimicking ferric iron enters bacteria cells and inhibit key bacterial enzymes, achieving a dual function.

Combination of existing drugs to combat resistant bacteria 

The combination of bismuth-based drugs and antibiotics has been proposed as a standard therapy for treating Helicobacter pylori infections in clinics. Sun’s team, for the first time, has applied this regimen to other multi-drug-resistant bacteria. Their study found that bismuth salicylate (Pepto-Bismol), when combined with different antibiotics, not only effectively eliminates multidrug-resistant Pseudomonas aeruginosa infections but also prevents the evolution of further antibiotic resistance.

This breakthrough highlights the potential of using bismuth-based drugs alongside specific clinically used antibiotics to combat Pseudomonas aeruginosa infections, which are notoriously difficult to treat given their rapid development of resistance.

Developing new antibiotics is both costly and time-consuming, while bacteria are quickly developing resistance, shortening the lifespan of effective antibiotics. As a result, combining existing drugs synergistically is emerging as a powerful alternative to combat the rise and spread of antibiotic-resistant bacterial strains.

Effective in over 100 resistant P. aeruginosa strains

This study demonstrates that bismuth disrupts iron homeostasis by specifically binding to a siderophore (molecules used by bacteria to obtain iron) and iron absorption regulator Fur in Pseudomonas aeruginosa. Within bacterial cells, bismuth specifically targets iron-sulfur cluster enzymes, leading to the inhibition of respiratory complexes.

This disruption impairs the electron transport chain and dissipates the proton motive force. Consequently, the activity of export pumps is damaged, resulting in the accumulation of antibiotics within the bacteria and enhancing their efficacy. At the same time, this approach also enhances the killing effect of antibiotics on bacteria within the biofilm.

The combined treatment also demonstrated powerful antibacterial effects in the bacterial infected cell models, and the team verified the effectiveness of this therapy in over 100 strains of clinically resistant Pseudomonas aeruginosa.

Finally, in a mouse lung infection model, the treatment significantly reduced bacterial colonisation in the lungs and improved the survival rate of mice. These findings lay a solid foundation for future efforts to combat drug-resistant bacterial infections and pave the way for further clinical applications.